Lorlatinib Interactions
There are 543 drugs known to interact with lorlatinib, along with 8 disease interactions, and 3 alcohol/food interactions. Of the total drug interactions, 143 are major, 386 are moderate, and 14 are minor.
- View all 543 medications that may interact with lorlatinib
- View lorlatinib alcohol/food interactions (3)
- View lorlatinib disease interactions (8)
Most frequently checked interactions
View interaction reports for lorlatinib and the medicines listed below.
- Aleve (naproxen)
- Aridol (mannitol)
- Ativan (lorazepam)
- Avastin (bevacizumab)
- Brevital Sodium (methohexital)
- Cerebyx (fosphenytoin)
- Claritin (loratadine)
- Clobex (clobetasol topical)
- CoQ10 (ubiquinone)
- Cosentyx (secukinumab)
- Coumadin (warfarin)
- Curcumin 95 (turmeric)
- Decadron with Xylocaine (dexamethasone / lidocaine)
- DHEA (dehydroepiandrosterone)
- Dilantin (phenytoin)
- Durezol (difluprednate ophthalmic)
- Eliquis (apixaban)
- Fish Oil (omega-3 polyunsaturated fatty acids)
- FUDR (floxuridine)
- GastroMARK (ferumoxsil)
- Geref Diagnostic (sermorelin)
- Ginkgo Biloba (ginkgo)
- Keytruda (pembrolizumab)
- Paracetamol (acetaminophen)
- Vitamin B12 (cyanocobalamin)
- Vitamin C (ascorbic acid)
- Vitamin D3 (cholecalciferol)
- Vitamin K2 (menaquinone)
- Xalkori (crizotinib)
- Xarelto (rivaroxaban)
Lorlatinib alcohol/food interactions
There are 3 alcohol/food interactions with lorlatinib.
Lorlatinib disease interactions
There are 8 disease interactions with lorlatinib which include:
- atrioventricular block
- CNS effects
- hepatotoxicity/hepatic impairment
- hyperglycemia
- hyperlipidemia
- hypertension
- interstitial lung disease
- severe renal impairment
Report options
More about lorlatinib
- lorlatinib consumer information
- Compare alternatives
- Side effects
- Dosage information
- During pregnancy
- Drug class: multikinase inhibitors
- Breastfeeding
- En español
Related treatment guides
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Opdivo Qvantig
Opdivo Qvantig is used to treat adults with melanoma, non-small cell lung cancer, renal cell ...
Rybrevant
Rybrevant is used to treat advanced non-small cell lung cancer (NSCLC) in adults that has certain ...
Enhertu
Enhertu is a treatment for breast cancer, stomach cancer, and non-small cell lung cancer with HER2 ...
Opdivo
Opdivo is used to treat many cancers, such as melanoma, non-small cell lung cancer, malignant ...
Keytruda
Keytruda is used to treat melanoma, non-small cell lung cancer, malignant pleural mesothelioma ...
Avastin
Avastin is used to brain tumors and cancers of the kidney, colon, rectum, or lung. Learn about side ...
Tagrisso
Tagrisso (osimertinib) may be used to treat adults with non-small cell lung cancer (NSCLC) whose ...
Gemcitabine
Gemcitabine is used for breast cancer, breast cancer, metastatic, nasopharyngeal carcinoma, non ...
Nivolumab
Nivolumab is used to treat melanoma, non-small cell lung cancer, malignant pleural mesothelioma ...
Paclitaxel
Paclitaxel is used for breast cancer, breast cancer, adjuvant, breast cancer, metastatic, kaposi's ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
